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Abstract: Leishmaniasis is a neglected parasitic protozoal disease that affects approximately 12 million people and represents a public health problem in Iran. 
The objectives of this study were to obtain the essential oil (EO) from Pulicaria vulgaris Gaertn. growing in Iran and to carry out in-vitro antileishmanial screening 
of the EO against promastigotes of Leishmania major and Leishmania infantum. The EO from the aerial parts of P. vulgaris was extracted by hydrodistillation. 
Serial dilutions of the EO were screened for in-vitro antileishmanial activity using 96-well microtiter plates. The P. vulgaris EO was active against the promastigote 
forms of L. major and L. infantum, with IC50 values of 244.70 and 233.65 µg/mL, respectively. Pulicaria vulgaris EO may serve as an alternative or complementary 
treatment for leishmaniasis.
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Introduction
An estimated two million people per year are afflic-
ted by the parasitic protozoal disease leishmaniasis (1). 
Leishmaniasis presents a wide spectrum of clinical ma-
nifestations from cutaneous lesions to visceral distress 
(2-4). Visceral leishmaniasis is a serious threat to child-
ren’s health. In endemic regions, children are at much 
greater risk compared to adults. Paediatric leishmaniasis 
presents symptoms that include paleness, intermittent 
fever, tendency to anorexia, abdominal distension, and 
weight loss, as well as hepatomegaly, splenomegaly, 
lymph node enlargement, anaemia, thrombocytopaenia, 
hypergammaglobulinemia and leukopaenia (5).
Protocols for the treatment of leishmaniasis remain 
problematic; currently available chemotherapeutics are 
associated with various limitations including the need 
for long-term treatments, adverse side effects, and li-
mited or reduced efficacy (4). As a result, there is an 
urgent need to find novel therapeutic agents or treatment 
regimens that are effective in treating leishmaniasis.
In recent years, phytotherapy has been shown to be 
useful for treatment of many human and animal diseases 
(6-18). However, plants have been immensely utilized 
in traditional healing systems, and in only a few cases 
have their curative potentials in human diseases been 
confirmed (19-27). Essential oils (EOs) are one of the 
options that have been recently used to treat a variety of 
diseases. EOs are complex mixtures of aromatic plant 
secondary metabolites, volatile, and lipophilic (28-30). 
Health care researchers and practitioners increasingly 
consider use of EO-bearing plants.
The genus Pulicaria Gaertn. (Asteraceae), accor-
ding to Iranica flora, includes five species that exist in 
Iran: P. dysenterica (L.) Bernh., P. arabica (L.) Cass., 
P. gnaphalodes (Vent.) Boiss., P. salvifolia Bunge and 
P. vulgaris Gaertn. P. vulgaris is an annual plant that 
has many branched reddish stems and small (6-12 mm) 
yellow flower heads. To our knowledge, there have been 
no previous studies on the anti-leishmanial activity P. 
vulgaris EO.
Materials and Methods
Pulicaria vulgaris Gaertn. was collected during the 
flowering period, March 2014, from the area surroun-
ding Hamun Lake, Zabol, in Sistan and Baluchestan 
Province of Iran. The plant species was identified at 
Ferdowsi University, where a voucher specimen (no. 
26432) was deposited in Mashhad Herbarium. For the 
EO extraction, the dried aerial parts (stems, leaves, and 
flowers) (200 g) of P. vulgaris were subjected to hydro-
distillation for 3 hours using a Clevenger-type apparatus 
based on method described by the British Pharmaco-
poeia (31). The EO obtained was dried using anhydrous 
sodium sulphate (Sigma-Aldrich Corp., St. Louis, MO, 
USA) and the EO obtained was stored at 4°C until ana-
lysis and further assays.
The EO of P. vulgaris initially was dissolved in 5% 
dimethyl sulphoxide (DMSO) (Sigma-Aldrich Corp., 
St. Louis, MO, USA)/95% water and further diluted 
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with RPMI 1640 medium (GIBCO, Grand Island, New 
York, USA). The concentration of DMSO in the wells 
was not higher than 0.01%. For assessing the antileish-
manial activity of the EO, logarithmic phase promas-
tigotes of Leishmania major (MRHO/IR/75/ER) and 
Leishmania infantum (MCAN/IR/96/LON49) (1 × 106 
cells/mL) were seeded in a 96-well microtiter plate 
along with serial dilutions (600, 300, 150, 100, 50, 25, 
20, 10, 5, and 0 µg/mL w/v) of the EO and afterwards 
incubated at 24°C, for 72 hours. Antileishmanial acti-
vity was determined by light microscope and the MTT 
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide, Sigma-Aldrich Corp., St. Louis, MO, USA] 
assay. The concentration inhibiting parasite growth by 
50% (IC50) was calculated by using the formula: EXP 
(LN (conc >50%) ‐ ((signal >50%‐50)/ (signal >50%‐
signal<50%)*LN (conc >50%/conc <50%))); where 
EXP is exponential and LN is natural logarithm (32).
Statistical analysis
Data obtained were subjected to analysis of variance 
(ANOVA) following a completely random design to 
determine the least significant difference (LSD) at P < 
0.05 by SPSS v. 11.5. All assays were carried out in tri-
plicate.
Results and Discussion
The % survival of L. infantum and L. major promas-
tigotes after 72 hours treatment, with various concentra-
tions of P. vulgaris EO is shown in Table 1.
The results of this study showed that P. vulgaris EO 
had anti-leishmanial effects. In particular, P. vulgaris 
EO was active against the promastigote forms of L. ma-
jor and L. infantum, with IC50 values of 244.7 and 233.6 
µg/mL, respectively. DMSO, used as the co-solvent for 
the EO, served as negative control, and had no effect 
on survival of L. major and L. infantum promastigotes. 
Torres-Santos et al. (33) have reported an IC50 value of 
83 µg/mL for glucantime as antileishmanial drug.
Sharifi-Rad et al. (32) investigated the chemical 
composition of P. vulgaris EO from the Zabol region. 
They reported that the main components were thymol, 
p-menth-6-en-2-one (carvotanacetone), thymol isobu-
tyrate, menthan-2-one, 1-methyl-1,2-propanedione, 
2,5-dimethoxy-p-cymene, myrtenol, linalool, and 
β-myrcene with 50.2%, 20.2%, 16.9%, 4.3%, 4.1%, 
4.0%, 1.2%, 1.1%, and 1.9% in the EO, respectively 
(Table 2).
The high thymol content in P. vulgaris EO is notable; 
thymol has shown in vitro and in vivo antileishmanial 
activity against Leishmania panamensis (34) and L. 
infantum ssp. chagasi (35). In terms of effectiveness, 
the EO of this plant is certainly more active than the 
main components alone. However, antileishmanial acti-
vity of P. vulgaris EO was not as active as glucantime, 
and several essential oils reported in the literature have 
shown leishmanicidal activities with IC50 in the range of 
2 to 100 μg/mL (36). Therefore, for example, Bursera 
graveolens EO, rich in limonene (26.5%), β-elemene 
(14.1%), and (E)-β-ocimene (13.0%), had IC50 = 36.7 
μg/mL against Leishmania amazonensis amastigotes 
(37), and Artemisia absinthium EO, rich in trans-sabinyl 
acetate, had IC50 = 13.4 μg/mL against L. amazonensis 
amastigotes (38). Nevertheless, the leishmanicidal acti-
vity of P. vulgaris EO is comparable to the activities of 
many other EOs (39). According to the results, it seems 
that P. vulgaris EO can be a promising candidate for dis-
Survival (%)
Concentration (µg/mL) Leishmania major Leishmania infantum
0 100 ± 00§ a 100 ± 0.0 a
5 100 ± 00 a 95.56 ± 0.11 b
10 90.54 ± 1.25 b 94.34 ± 0.23 b
25 89.32 ± 0.28 c 90.56 ± 0.23 c
50 79.93 ± 1.32 d 85.55 ± 0.44 d
100 74.23 ± 1.11 d 79.45 ± 0.13 e
150 60.52 ± 1.22 e 69.59 ± 0.45 f
300 45.62 ± 2.35 f 38.95 ± 1.22 g
600 25.64 ± 1.52 g 18.54 ± 0.32 h
DMSO - -
Table 1. Percent survival of Leishmania major and Leishmania infantum promastigotes after 72 hours treatment with 
different concentrations of Pulicaria vulgaris essential oil.
§Data are expressed as mean ± SD of % viability for different concentrations of EO and controls. Significant 
differences of EO effects on survival of Leishmania major and Leishmania infantum promastigotes are indicated with 
different letters for each Leishmania species. That is, in each column, the values that have given different letter were 
significantly different in comparison with other values in the column, while the values with same letters in the each 
column represent those values having no significant difference with other values in the column at P < 0.05.
Plant name Collection area Major components References
P u l i c a r i a 
v u l g a r i s 
Gaertn.
Hamun Lake, 
Zabol, Iran
Thymol (50.22%), p-menth-6-en-2-one (carvotanacetone, 20.2%), thymol 
isobutyrate (16.88%), menthan-2-one (4.31%), 1-methyl-1,2-propanedione 
(4.13%), 2,5-dimethoxy-p-cymene (4.01%), myrtenol (1.22%), linalool (1.1%), 
β-myrcene (1.9%).
Sharifi-Rad 
et. (32)
Table 2. Major components of essential oil of Pulicaria vulgaris.
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covery of new natural antileishmanial drugs, especially 
in terms of paediatric leishmaniasis.
Today, many classes of synthetic antileishmanial 
drugs are showing diminishing effectiveness because 
of the emergence of drug-resistant strains. Hence, using 
effective natural antileishmanial agents with fewer side 
effects is an encouraging approach to combat leish-
maniasis. However, these preliminary antileishma-
nial screening used the promastigote (insect) form of 
the parasite rather than the intracellular (amastigote) 
form. Therefore, more studies are needed to examine 
in vivo antileishmanial effects of P. vulgaris EO, iden-
tify mechanism(s) of activion and investigate adverse 
effects.
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